Loss of Intra-Islet CD20 Expression May Complicate Efficacy of B-Cell–Directed Type 1 Diabetes Therapies

OBJECTIVE: Consistent with studies in NOD mice, early clinical trials addressing whether depletion of B cells by the Rituximab CD20-specific antibody provides an effective means for type 1 diabetes reversal have produced promising results. However, to improve therapeutic efficacy, additional B-cell–...

Descripción completa

Detalles Bibliográficos
Autores principales: Serreze, David V., Chapman, Harold D., Niens, Marijke, Dunn, Robert, Kehry, Marilyn R., Driver, John P., Haller, Michael, Wasserfall, Clive, Atkinson, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198088/
https://www.ncbi.nlm.nih.gov/pubmed/21926271
http://dx.doi.org/10.2337/db11-0705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198088/
https://www.ncbi.nlm.nih.gov/pubmed/21926271
http://dx.doi.org/10.2337/db11-0705

Ejemplares similares